小脑HGNET-BCOR肿瘤—3例小脑HGNET-BCOR肿瘤的临床病理与分子特征
  ——本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意,否则追究法律责任。

  具有BCOR的中枢神经系统( central nervous system,CNS )高级神经上皮肿瘤 ( high-grade neuroepithelial tumor,HGNET)(CNS HGNET-BCOR)是最近描述的一种分子实体。我们报告3例具有相同临床表现和病理特点的CNS HGNET-BCOR新病例。3例均为儿童病例,年龄3~7岁,表现出小脑巨大占位性病变。病理学特征包括一致的、具有纤细染色质的梭形到卵圆形细胞的增生,与丰富的树枝状毛细血管网。甲基化分析将这些病例归入CNS HGNET-BCOR肿瘤。聚合酶链式反应分析证实,这3例病例存在BCOR羧基端内部串联重复(internal tandem duplications in the C-terminus of BCOR,BCOR-ITD),就是这些肿瘤的特征。免疫组化染色显示核BCOR强表达。其中2例在手术后6个月内局部复发,第3例在手术完全切除后接受全脑全脊髓放疗,随后接受伊立替康、替莫唑胺和伊曲康唑节拍式化疗,在诊断14个月后仍保持无病状态。总的来说,CNS HGNET-BCOR是一种罕见的、发生于年轻患者预后较差的肿瘤。BCOR核表达高度提示BCOR-ITD。CNS HGNET-BCOR 应归入“ 胚胎性肿瘤 ”类别还是“间叶性、非脑膜上皮性肿瘤”有待于进一步阐明。由于CNS HGNET-BCOR 与肾透明细胞肉瘤享有相同的病理学特征和特征性的BCOR-ITD,因此,这些肿瘤可能是相同实体不同部位的亚型。
  Am J Surg Pathol 2017;41:1254–1260
美国外科病理学杂志中文版2018年第一期摘要No.5
  (张声 翻译/审校)
  The American Journal of Surgical Pathology中文版声明:
  2018 Wolters Kluwer Health
  The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
  Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
 
  【本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意 ,否则追究法律责任;所有文章仅供公益交流,不代表本站立场。欢迎提供素材、资料等,投稿邮箱: tougao@91360.com,一经采纳将给予稿费】